Taysha Gene Therapies (TSHA) Share-based Compensation (2019 - 2026)

Taysha Gene Therapies has reported Share-based Compensation for 7 years, with the latest figure at $28.1 million in Q1 2026.

• Quarterly Share-based Compensation rose 753.07% year-over-year to $28.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.1 million (up 112.89% YoY) and the FY2025 annual result came in at $13.3 million, down 14.21% from the prior year.
• Share-based Compensation rose to $28.1 million in Q1 2026 per TSHA's latest filing, from $3.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $28.1 million in Q1 2026 and troughed at $1.7 million in Q1 2023.
• A 5-year average of $4.7 million and a median of $3.3 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2026: Share-based Compensation plunged 68.57% in 2023, then soared 753.07% in 2026.
• Over 5 years, Share-based Compensation stood at $4.1 million in 2022, then sank by 52.04% to $2.0 million in 2023, then surged by 63.41% to $3.2 million in 2024, then gained by 9.73% to $3.5 million in 2025, then soared by 696.26% to $28.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $28.1 million, $3.5 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.